Treatment of glaucoma using prostaglandin-F2α derivatives;Glaukomtherapie mit prostaglandin-F2α-derivaten

Ophthalmologe

Volumn 94, Issue 10, 1997, Pages 754-769

  Diestelhorst, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; PROSTAGLANDIN F2 ALPHA DERIVATIVE; UNOPROSTONE ISOPROPYL ESTER;

DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; GLAUCOMA; HUMAN; REVIEW; TREATMENT PLANNING;

ANIMALS; CLINICAL TRIALS; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS F, SYNTHETIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030714602     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003470050200     Document Type: Review

References (50)

1. Adam M, Boie Y, Ruishmore TH, Muller G, Bastien L, McKee KT, Metters KM, Abramovitz M (1994) Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett 338-170-174
2. Alm A, Villumsen J (1989) Effects of topically applied PG-F2α and its isopropylester on normal and glaucomatous human eyes. In: Bito LZ, Stjernschatz J (eds) The ocular effects of prostaglandins and other eicosanoids. New York, Liss, pp 447-458
3. Alm A, Villumsen J (1991) PhXA34, a new potent ocular hypotensive drug. Arch Ophthalmology 109:1564-1568
4. Alm A (1993) The potential of prostagtandin derivates in glaucoma therapy. Curr Opin Ophthalmol 4:44-50
5. Alm A, Villumsen J, Tornquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J (1993) Intraocular pressure-reducing effect of PHXA41 in patients with increased eye pressure. Ophthalmol 9:1312-1317
6. Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, Stjernschantz J (1995) Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1:12-16
7. Ambache N (1955) Irin, a smooth-muscle contracting substance present in rabbit iris. J Physiol 129:65-66
8. Alm A, Stjernschantz J, he Scandinavian Latanoprost Study Group (1995) Effects on intraocular pressure an side effects of 0,005% latanoprost once daily, evening or morning. A comparison with timolol. Ophthalmology 102:1743-1752
9. Astin M, Gjotterberg M, Holst A, Selén G, Resul B, Stjernschantz J (1992) Study of the fundus in phakic and aphakic monkey eyes treated with PhXA41. Invest Ophthalmol Vis Sci 33 (suppl):1078
10. Astin M, Stjernschantz J, Selén G (1994) Role of nitric oxide in PG-F2α-induced ocular hyperemia. Exp Eye Res 1994;59:401-408
11. Basu S, Sjoquist B, Stjernschantz J, Resul B (1994) Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukotrienes Essent Fatty Aci 50:161-168
12. Bito LZ, Cannas CB, Glenwood GG, Resul R (1989) The ocular hypotensive effects and side effects of prostaglandins an the eyes of experimental animals. In Bito LZ, Stjernschantz J (eds) The ocular effects of prastaglandins and other eicosanoids. New York, Liss, pp 349-368
13. Camras CC, Bito LZ (1981) Reduction of intraocular pressure in normal and glaucomatous primate (Aoutus trivirgatus) eyes by topically applied prostaglandin F2α. Curr Eye Res 1:205-209
14. Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM (1992) Intra-ocular pressure reduction with PhXA34, a new prostalandin analogue, in patients with ocular hypertension. Arch Ophthalmol 110:1733-1738
15. Camras CB, Alm A, Watson P (1995) Glaucoma treatment für 1 year with latanoprost, a prostaglandin analog, in the USA, Scandinavia and UK. American Academy of Ophthalmology, Annual Meeting, Atlanta, p 89
16. Camras CB, the rest of the USA Latanoprost Study Group (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma-six-month, masked U.S.A. multicenter trial. Ophthalmol 103:138-147
17. Coleman RA, Smith WL, Narumiya S (1994) International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46 205-229
18. Crawford K, Kaufman PL (1987) Pilocarpine antagonizes PG-F2α-induced ocular hypotension: evidence for enhancement of uveoscleral outflow by PG-F2α. Arch Ophthalmol 105:1112-1116
19. Diestelhorst M, Roters S, Krieglstein GK (1997) The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure an aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol 235:20-26
20. Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S (1997) Clinical Dose-Regimen Studies with Latanoprost, a New Ocular Hypotensive PG-F2α Analogue. Surv Ophthalmol 41[Suppl 2]:77-81
21. Diestelhorst M, for the German Latanoprost Study Group (1997) Comparison of two fixed combinations of Latanoprost and Timolol in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol (eingereicht)
22. Fristrom B, Nilsson SEG (1993) Interaction of PhX41, a new prostaglandin analogue, with pilocarpine. Arch Ophthalmol 111 662-665
23. Gabelt TBA, Kaufman PL (1989) Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49:389-402
24. Green K, Paterson CA, Siddiqui A (1985) Ocular blood flow after experimental alkali burns and prostaglandin administration. Arch Ophthalmol 103:569-571
25. Hotehama Y, Mishima HK (1993) Clinical efficacy of PHXA34 and PhXA41, tow novel prostaglandin F2α-isopropylester analogues for glaucoma treatment. Jpn J Ophthalmol 37:259-269
26. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K (1993) Ocular hypotensive effect of PNXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol 37:270-274
27. Hu F, Mah K (1983) Changes in melanosomes with age in iridial stromal melanocytes of rhesus macques. Mech Ageing Dev 23:95-102
28. Jarkman SH, Bragadóttir R, Nilsson SEG (1994) Effects of PG-F2α and PHXA41, a prostaglandin analogue, on the corneal and intraretinal d.c. electroretinogram (ERG) of the albino rabbit eye. Invest Ophthalmol Vis Sci 35[Suppl]:A3661
29. Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A (1995) The short-time effect of Iatanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 73 233-236
30. Lutjen-Drecoll E, Tamm E (1988) Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α. Exp Eye Res 47:761-769
31. Mauger TF, Craig EL (1994) Pilocarpine. In Havener's ocular pharmacology, 6th edn. Mosby, St. Louis, pp 116-124
32. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J (1993) Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Ophthalmology 9:1305-1311
33. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J (1989) Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in die cynomolgus monkey. Exp Eye Res 48:707-716
34. Ocklind A, Lake S, Wentzel P, Krook K, Johansson B, Stjernschantz J (1995) Localization of the prostaglandin F2α receptor in the monkey eye. Invest Ophthalmol Vis Sci 36 [Suppl]:A2765
35. Pierce KL, Gil DW, Woodward DF, Regan JW (1995) Cloning of human prostanoid receptors. Trends Pharmacol Sci 16:253-256
36. Rácz P, Ruzsonyi, MR, Nagy ZT, Bito LZ (1993) Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2α analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol 111:657-661
37. Rácz P, Ruzsonyi MR, Nagy ZT, Gagyi Z, Bito LZ (1996) Around-the-clock (circadian) intraocular pressure reduction with once-daily application of 0,005% latanoprost, by itself or in combination with timolol. Arch Ophthalmol 114:268-273
38. Rulo AH, Greve EL, Hoyng PF (1994) Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 78:899-902
39. Rulo AH, Greve EL, Hoyng PFJ (1995) The ocular hypotensive effect of latanoprost in normal pressure glaucoma patients. Invest Ophthalmol Vis Sci 36 (suppl):A3421
40. Selén G, Stjernschantz J, Resul B, (1997) Prostaglandin-induced iridial pigmentation in primates. Survey Ophthalmol 41 [Suppl 2]:S125-128
41. Sjoquist B, Johansson A (1995) The ocular pharmakokinetics of latanoprost, a new antiglaucoma drug, studies by autoradiography. Invest Ophthalmol Vis Sci 36[Suppl]:A3809
42. Stjernschantz J, Nilsson SFE, Astin M (1989) Vasodynamic and angiogenic effects of eicosanoids in the eye. In: Bito LZ, Stjernschantz J (eds) The ocular effects of prostaglandins and other eicosanoids.New York, Liss, pp 155-170
43. Stjernschantz J, Selén G, Sjoquist B, Resul B (1995) Preclinical pharmacology of latanoprost, a phenylsubstituted PG-F2α-analogue. In: Samuelsson B. et al (eds) Advances in prostaglandin, tromboxane, and leukotriene research, vol 23. New York, Raven Press, pp513-518
44. Sugimoto Y, Negishi M, Hayashi Y, Namba T, Honda A, Watabe A, Hirata M, Narumiya S, Ichikawa A (1993) Two isoforms of the EPB receptor with different carboxyl-terminal domains. J Biol Chem 268:2712-2718
45. Toris CB, Camras CB, Yablonski ME (1993) Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 100 1297-1304
46. Villumsen J, Alm A (1989) Prostaglandin F2α-isopropylester eye drops; effects in normal human eyes. Br J Ophthalmol 73:419-426
47. Villumsen J, Alm A (1992) PhXA34-a prostaglandin F2α analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 76:214-217
48. Watson P, Stjernschantz J, the Latanoprost Study Group in United Kingdom (1994) A six month randomized, double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 103:126-137
49. Weinreb RN, Kim D-M, Lindsey JD (1992) Propagation of ciliary smooth muscle cells in vitro and effects of prostaglandin F2α on calcium efflux. Invest Ophthalmol Vis Sci 33 2679-2686
50. Ziai N, Dolan WJ, Dacere RD, Brubaker RF (1993) The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 11:1351-1358